Comparison of LMWH Versus UFH for Hemorrhage and Hospital Mortality in the Treatment of Acute Massive Pulmonary Thromboembolism After Thrombolytic Treatment: Randomized Controlled Parallel Group Study

Lung

Volumn 193, Issue 1, 2015, Pages 121-127

  Ucar, Elif Yilmazel ^a   Akgun, Metin ^a   Araz, Omer ^a   Tas, Hakan ^a   Kerget, Bugra ^a   Meral, Mehmet ^a   Kaynar, Hasan ^a   Saglam, Leyla ^a  

^a ATATURK UNIVERSITY   (Turkey)

Author keywords

Low molecular weight heparin; Mortality; Pulmonary thromboembolism; Thrombolytic treatment; Unfractionated heparin

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; LUNG EMBOLISM; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; HEMORRHAGE; MIDDLE AGED; PULMONARY EMBOLISM; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; TURKEY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RISK ASSESSMENT; RISK FACTORS; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME; TURKEY; YOUNG ADULT;

EID: 84938083596     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-014-9660-z     Document Type: Article

References (29)

1. Horlander KT, Mannino DM, Leeper KV (2003) Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 163:1711–1717
2. Tapson VF (2008) Acute pulmonary embolism. N Engl J Med 358:1037–1052
3. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S–e494S
4. Quinlan DJ, McQuillan A, Eikelboom JW (2004) Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 140:175–183
5. Erkens PM, Prins MH (2010) Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev:CD001100
6. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P et al (2008) Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 29:2276–2315
7. Ucar EY, Araz O, Akgun M, Meral M, Kalkan F, Saglam L, Kaynar H, Gorguner AM (2013) Low-molecular-weight heparin use with thrombolysis: is it effective and safe? Ten years’ clinical experience. Respiration 86:318–323
8. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ et al (2011) Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 123:1788–1830
9. Jerjes-Sanchez C, Villarreal-Umana S, Ramirez-Rivera A, Garcia-Sosa A, Miguel-Canseco L, Archondo T et al (2009) Improving adjunctive treatment in pulmonary embolism and fibrinolytic therapy. The role of enoxaparin and weight-adjusted unfractionated heparin. J Thromb Thrombolysis 27:154–162
10. Morris TA, Castrejon S, Devendra G, Gamst AC (2007) No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis. Chest 132:1131–1139
11. van Den Belt AG, Prins MH, Lensing AW, Castro AA, Clark OA, Atallah AN, et al (2000) Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev:CD001100
12. Costantino G, Ceriani E, Rusconi AM, Podda GM, Montano N, Duca P et al (2012) Bleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review. PLoS ONE 7:e44553
13. Hull RD (2008) Treatment of pulmonary embolism: the use of low-molecular-weight heparin in the inpatient and outpatient settings. Thromb Haemost 99:502–510
14. Akl EA, Labedi N, Terrenato I, Barba M, Sperati F, Sempos EV, et al (2011) Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Cochrane Database Syst Rev:CD009447
15. Junqueira DR, Perini E, Penholati RR, Carvalho MG (2012) Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev 9:CD007557
16. Sandercock P, Counsell C, Stobbs SL (2005) Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database Syst Rev:CD000119
17. van Dongen CJ, van den Belt AG, Prins MH, Lensing AW (2004) Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev:CD001100
18. Marshall PS, Matthews KS, Siegel MD (2011) Diagnosis and Management of Life-Threatening Pulmonary Embolism. J Intensive Care Med [Epub ahead of print]
19. Kucher N, Goldhaber SZ (2005) Management of massive pulmonary embolism. Circulation 112:e28–e32
20. Piazza G, Goldhaber SZ (2010) Fibrinolysis for acute pulmonary embolism. Vasc Med 15:419–428
21. Thabut G, Thabut D, Myers RP, Bernard-Chabert B, Marrash-Chahla R, Mal H et al (2002) Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol 40:1660–1667
22. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW (2004) Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 110:744–749
23. Hull RD (2008) Treatment of pulmonary embolism: the use of low-molecular-weight heparin in the inpatient and outpatient settings. Thromb Haemost 99:502–510
24. Lankeit M, Konstantinides S (2011) Mortality risk assessment and the role of thrombolysis in pulmonary embolism. Crit Care Clin 27:953–967
25. Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, Meyer G, Perrier A (2014) Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J [Epub ahead of print]
26. Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, Kumbhani DJ, Mukherjee D, Jaff MR, Giri J (2014) Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA 311:2414–2421
27. Stein PD, Matta F (2012) Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med 125:465–470
28. Ozsu S, Ozlu T, Bulbul Y (2009) Pulmonary thromboembolism based on the Turkish national data. Tuberk Toraks 57:466–482
29. Lin BW, Schreiber DH, Liu G, Briese B, Hiestand B, Slattery D, Kline JA, Goldhaber SZ, Pollack CV Jr (2012) Therapy and outcomes in massive pulmonary embolism from the Emergency Medicine Pulmonary Embolism in the Real World Registry. Am J Emerg Med 30:1774–1781